Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces greater weight reduction than GLP-1 monotherapy in individuals with obesity without type 2 diabetes.
Tirzepatide 15 mg injected once weekly leads to an average 20.9% body weight loss in adults with obesity without diabetes over 72 weeks. This dual-action hormone therapy is more effective than GLP-1 monotherapy.
StrongSupportsVERY_HIGH confidence
The SURMOUNT-1 trial... demonstrated weight reduction that has not been previously demonstrated in phase III obesity treatment trials... participants who were randomized to the highest dose of tirzepatide (15 mg) lost 20.9% of their body weight, whereas the placebo group lost 3.1% (treatment difference of 17.8%)
Why this rating
Based on Phase III SURMOUNT-1 trial with 2,539 participants.
Source
New Frontiers in Obesity Treatment: GLP-1 and Nascent Nutrient-Stimulated Hormone-Based Therapeutics
Ania M. Jastreboff et al. · Annual Review of Medicine · 2023
narrative_reviewCited 148×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →